Microglial regulation of Progranulin levels
小胶质细胞对颗粒体蛋白前体水平的调节
基本信息
- 批准号:10347312
- 负责人:
- 金额:$ 62.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAffectAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAlzheimer&aposs disease riskBehavioralBehavioral AssayBiochemicalBiologyBrainCRISPR/Cas technologyCell Culture SystemDNA Sequence AlterationDataDementiaDevelopmentDiseaseEndocytosisFrontotemporal Lobar DegenerationsFutureGeneticGlycoproteinsGoalsGrantHomologous GeneHumanKnockout MiceKnowledgeLeadLinkMediatingMicrogliaMolecularMolecular TargetMusMutationNervous System PhysiologyNeurodegenerative DisordersNeuronal Ceroid-LipofuscinosisOnset of illnessPGRN genePathologicPathologyPathway interactionsPatientsPhenotypePhosphotransferasesPlasmaProtein-Serine-Threonine KinasesProteinsProteomicsRegulationResearchRoleSingle Nucleotide PolymorphismSymptomsTestingTherapeutic InterventionValidationbasebehavioral phenotypingdosageefficacy testinggranulinhuman diseaseimprovedin vivoinduced pluripotent stem cellinsightloss of functionmouse geneticsnemo-like kinasenervous system disorderneuropathologynovel therapeutic interventionoverexpressionpatient subsetspreventreceptortargeted treatmenttherapeutic developmenttherapeutically effectivetrafficking
项目摘要
Genetic mutations in Granulin (GRN) that result in reduced levels of its encoded protein, progranulin (PGRN),
have been implicated in several distinct neurological disorders, depending on the degree of PGRN reduction.
More specifically, haploinsufficiency resulting from heterozygous GRN mutations has been identified to be
causal for a subset of patients with frontotemporal lobar degeneration (FTLD), an adult-onset
neurodegenerative disease. Furthermore, homozygous loss-of-function GRN mutations result in neuronal
ceroid lipofuscinosis (NCL), and single nucleotide variants that decrease plasma and brain PGRN levels are
risk factors for Alzheimer’s Disease (AD). The clear association between reduced levels of PGRN and
neurological disorders highlights the importance of adequate PGRN dosage in normal nervous system
function. The overarching goal of this project is to better understand the precise cellular and molecular
mechanisms that are involved in the regulation of PGRN. In order to reach this goal, we began by identifying
factors that could potentially modulate phenotypes associated with PGRN haploinsufficiency. The preliminary
data presented in this application clearly show that Nemo-like kinase (NLK), an evolutionarily conserved
serine/threonine kinase, is involved in the regulation of PGRN levels and can modulate phenotypes associated
with PGRN reduction in vivo through microglia. To investigate this idea further, we propose the following three
specific aims. In Specific Aim 1, we will determine whether altering Nlk levels specifically in microglia can
modulate FTLD-related phenotypes in vivo using mouse genetics. Specifically, (1) we will first test whether
constitutive loss of Nlk in microglia is able to induce FTLD-related neuropathological and behavioral
phenotypes. (2) Conversely, we will examine if constitutive overexpression of Nlk in microglia can prevent or
ameliorate these same phenotypes. We will focus on neuropathological changes and behavioral deficits that
have been previously ascribed to PGRN reduction in FTLD-PGRN patients and Grn knockout mice. In Specific
Aim 2, we will elucidate the molecular mechanism through which Nlk regulates Pgrn levels in microglia. We will
(1) employ mouse genetics and isogenic human induced pluripotent stem cell-derived microglia to determine
the receptor involved in Nlk-mediated regulation of Pgrn endocytosis and (2) utilize unbiased proteomics
approaches to identify direct molecular targets of Nlk that function in this regulation. In Specific Aim 3, we will
determine whether GRN-associated neuropathology can be suppressed or reversed by increasing Nlk
expression in adulthood. To do this, we will temporally induce the overexpression of Nlk after disease onset
and test the efficacy in ameliorating or reversing pathological and behavioral deficits. We believe that the
knowledge gained from the studies proposed in this application will advance our basic understanding of the
cellular and mechanism underlying PGRN regulation and will suggest new therapeutic interventions aimed at
reducing the burden of FTLD and other neurological disorders associated with PGRN reduction such as AD.
颗粒蛋白(GRN)中的遗传突变导致其编码蛋白的水平降低,PGRN(PGRN),
根据PGRN降低程度,已经暗示了几种不同的神经系统疾病。
更具体地说,杂合子GRN突变引起的单倍不足已被确定为
成人发作的额颞Lobar变性(FTLD)的子集的因果关系
神经退行性疾病。此外,纯合功能丧失的GRN突变导致神经元
ceroid脂肪促肌动病(NCL)和降低血浆和脑PGRN水平的单个核苷酸变体是
阿尔茨海默氏病(AD)的危险因素。 PGRN水平降低和
神经系统疾病强调了正常神经系统中足够的PGRN剂量的重要性
功能。该项目的总体目标是更好地了解精确的细胞和分子
涉及PGRN的机制。为了实现这一目标,我们首先要确定
可能会调节与PGRN单倍宽度相关的表型的因素。初步
本应用程序中介绍的数据清楚地表明,类似NeMo样激酶(NLK),一种进化保守的
丝氨酸/苏氨酸激酶参与PGRN水平的调节,可以调节相关的表型
通过小胶质细胞在体内降低PGRN。为了进一步调查这个想法,我们提出了以下三个
具体目标。在特定的目标1中,我们将确定在小胶质细胞中专门改变NLK水平是否可以
使用鼠标仿制药在体内调节与FTLD相关的表型。具体来说,(1)我们将首先测试是否
小胶质细胞中NLK的组成型损失能够诱导与FTLD相关的神经病理学和行为
表型。 (2)相反,我们将检查小胶质细胞中NLK的构型过表达是否可以预防或
改善这些相同的表型。我们将专注于神经病理学的变化和行为缺陷
以前已归因于FTLD-PGRN患者和GRN敲除小鼠的PGRN降低。具体
AIM 2,我们将阐明NLK调节小胶质细胞中PGRN水平的分子机制。我们将
(1)就业小鼠遗传学和同源性人类诱导的多能干细胞衍生的小胶质细胞来确定
参与NLK介导的PGRN内吞作用调节的接收器,(2)利用无偏的蛋白质组学
确定在此调节中起作用的NLK的直接分子靶标的方法。在特定的目标3中,我们将
确定是否可以通过增加NLK来抑制或逆转与GRN相关的神经病理学
在成年中的表达。为此,我们将暂时诱导疾病发作后NLK的过表达
并测试改善或逆转病理和行为缺陷的有效性。我们相信
从本应用中提出的研究中获得的知识将提高我们对
PGRN调节的基础细胞和机制,将提出针对的新治疗干预措施
减轻FTLD和其他与PGRN减少相关的神经系统疾病的负担,例如AD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janghoo Lim其他文献
Janghoo Lim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janghoo Lim', 18)}}的其他基金
Investigation of the role of ATXN1 in oligodendroglia and neurodegenerative diseases
ATXN1 在少突胶质细胞和神经退行性疾病中的作用研究
- 批准号:
10762709 - 财政年份:2022
- 资助金额:
$ 62.32万 - 项目类别:
Investigation of the role of ATXN1 in oligodendroglia and neurodegenerative diseases
ATXN1 在少突胶质细胞和神经退行性疾病中的作用研究
- 批准号:
10390899 - 财政年份:2022
- 资助金额:
$ 62.32万 - 项目类别:
Investigation of the role of ATXN1 in oligodendroglia and neurodegenerative diseases
ATXN1 在少突胶质细胞和神经退行性疾病中的作用研究
- 批准号:
10576381 - 财政年份:2022
- 资助金额:
$ 62.32万 - 项目类别:
Investigation of the role of ATXN1 in oligodendroglia and neurodegenerative diseases
ATXN1 在少突胶质细胞和神经退行性疾病中的作用研究
- 批准号:
10632309 - 财政年份:2022
- 资助金额:
$ 62.32万 - 项目类别:
Evaluation of a novel NLK function in lysosome biogenesis and neurodegenerative diseases
溶酶体生物合成和神经退行性疾病中新的 NLK 功能的评估
- 批准号:
10458774 - 财政年份:2021
- 资助金额:
$ 62.32万 - 项目类别:
Evaluation of a novel NLK function in lysosome biogenesis and neurodegenerative diseases
溶酶体生物合成和神经退行性疾病中新的 NLK 功能的评估
- 批准号:
10616786 - 财政年份:2021
- 资助金额:
$ 62.32万 - 项目类别:
Evaluation of a novel NLK function in lysosome biogenesis and neurodegenerative diseases
溶酶体生物合成和神经退行性疾病中新的 NLK 功能的评估
- 批准号:
10317219 - 财政年份:2021
- 资助金额:
$ 62.32万 - 项目类别:
Microglial regulation of Progranulin levels
小胶质细胞对颗粒体蛋白前体水平的调节
- 批准号:
10092071 - 财政年份:2020
- 资助金额:
$ 62.32万 - 项目类别:
Microglial regulation of Progranulin levels
小胶质细胞对颗粒体蛋白前体水平的调节
- 批准号:
10536631 - 财政年份:2020
- 资助金额:
$ 62.32万 - 项目类别:
Microglial regulation of Progranulin levels
小胶质细胞对颗粒体蛋白前体水平的调节
- 批准号:
9917026 - 财政年份:2020
- 资助金额:
$ 62.32万 - 项目类别:
相似国自然基金
海洋缺氧对持久性有机污染物入海后降解行为的影响
- 批准号:42377396
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
氮磷的可获得性对拟柱孢藻水华毒性的影响和调控机制
- 批准号:32371616
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
还原条件下铜基催化剂表面供-受电子作用表征及其对CO2电催化反应的影响
- 批准号:22379027
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CCT2分泌与内吞的机制及其对毒性蛋白聚集体传递的影响
- 批准号:32300624
- 批准年份:2023
- 资助金额:10 万元
- 项目类别:青年科学基金项目
在轨扰动影响下空间燃料电池系统的流动沸腾传质机理与抗扰控制研究
- 批准号:52377215
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Uncovering Mechanisms of Racial Inequalities in ADRD: Psychosocial Risk and Resilience Factors for White Matter Integrity
揭示 ADRD 中种族不平等的机制:心理社会风险和白质完整性的弹性因素
- 批准号:
10676358 - 财政年份:2024
- 资助金额:
$ 62.32万 - 项目类别:
The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
- 批准号:
10748606 - 财政年份:2024
- 资助金额:
$ 62.32万 - 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
- 批准号:
10749539 - 财政年份:2024
- 资助金额:
$ 62.32万 - 项目类别:
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathies
持续的 eIF5A 抑制是 TDP-43 蛋白病脑代谢功能障碍的核心
- 批准号:
10557547 - 财政年份:2023
- 资助金额:
$ 62.32万 - 项目类别:
Defining the Role of Enteric Nervous System Dysfunction in Gastrointestinal Motor and Sensory Abnormalities in Down Syndrome
确定肠神经系统功能障碍在唐氏综合症胃肠运动和感觉异常中的作用
- 批准号:
10655819 - 财政年份:2023
- 资助金额:
$ 62.32万 - 项目类别: